. 2022 Mar 31;8(2):91–99. doi: 10.1002/cdt3.18

Table 1.

Clinical trials using immunotherapy for patients with unresectable malignant pleural mesothelioma

NCT number	Trial name	Phase	Regimen	Primary endpoints	Line	No. patients	Status	Results
NCT02497508	NivoMes	Ⅱ	Nivolumab	12W DCR	At least 2nd line or more	38	Completed	12W DCR, 47%
JapCTI‐163247	MERIT	Ⅱ	Nivolumab	ORR	At least 2nd line or more	34	Completed	ORR, 26%
NCT02716272	MAPS2	Ⅱ	Nivolumab versus	12W DCR	At least 2nd line or more	125	Completed	12W DCR, 44% versus 50%
NCT02716272	MAPS2	Ⅱ	Nivolumab + Ipilimumab	12W DCR	At least 2nd line or more	125	Completed	12W DCR, 44% versus 50%
NCT03048474	INITIATE	Ⅱ	Ipilimumab + Nivolumab	12W DCR	At least 2nd line or more	35	Completed	12W DCR, 68%
NCT03063450	CONFIRM	Ⅲ	Nivolumab versus placebo	PFS/OS	At least 2nd line or more	332	Completed	PFS, 3.0 versus 1.8 months; OS, 9.2 versus 6.6 months
NCT02054806	KEYNOTE‐028	Ⅰb	Pembrolizumab	ORR	At least 2nd line or more	25	Active, not recruiting	ORR, 20%
NCT02628067	KEYNOTE‐158	Ⅱ	Pembrolizumab	ORR	At least 2nd line or more	118	Completed	ORR, 10%
NCT02991482	PROMISE‐Meso	Ⅲ	Pembrolizumab versus CT (gemcitabine or vinorelbine)	PFS	At least 2nd line or more	114	Active, not recruiting	PFS, 2.5 versus 3.4 months
NCT01772004	JAVELIN	Ⅰb	Avelumab	ORR	At least 2nd line or more	53	Completed	ORR, 9%
NCT02588131	NIBIT‐Meso‐1	Ⅱ	Tremelimumab + Durvalumab	ORR	At least 2nd line or more	40	Completed	ORR, 28%
NCT01649024	MESOT‐TREM‐2008	Ⅱ	Tremelimumab	ORR	At least 2nd line or more	25	Completed	ORR, 7%
NCT01655888	MESOT‐TREM‐2012	Ⅱ	Tremelimumab	ORR	At least 2nd line or more	29	Completed	ORR, 13.8%
NCT01843374	DETERMINE	Ⅱb	Tremelimumab versus placebo	OS	At least 2nd line or more	571	Completed	OS, 7.7 versus 7.3 months (p = 0.41)
NCT02899299	Checkmate 743	Ⅲ	Ipilimumab + Nivolumab versus CT	OS	First line	92	Completed	OS, 18.1 versus 14.1 months (p = 0.0020)
NCT02899195	PrE505	Ⅱ	Durvalumab + CT	OS	First line	55	Completed	OS, 21.1 months
ACTRN	DREAM	Ⅱ	Durvalumab	PFS rate at 6 months	First line	54	Completed	PFS rate at 6 months, 57%
12616001170415	DREAM	Ⅱ	Durvalumab	PFS rate at 6 months	First line	54	Completed	PFS rate at 6 months, 57%
NCT04334759	DREAM3R	Ⅲ	Durvalumab + CT versus CT	OS	First line	480	Recruiting	—
NCT03762018	ETOP BEAT‐meso	Ⅲ	Atezolizumab + CT + bevacizumab versus CT + bevacizumab	PFS/OS	First line	320	Recruiting	—

Abbreviations: 12W DCR, disease control rate at 12 weeks; CT, chemotherapy; ORR, overall response rate; OS, overall survival; PFS, progression‐free survival.